New client signs with Cognition Kit software

We’re delighted to announce a new $0.5m contract with a major pharmaceutical company for the use of our Cognition Kit digital health software in a clinical trial.

Cognition Kit measures cognitive health on mobile and wearable devices, enabling researchers to gather data in everyday life and clinicians to make more insightful treatment decisions for their patients.

This clinical trial will monitor patients diagnosed with a neurological condition for 12 months. During this time, participants will use a Cognition Kit smartphone app to test their brain health remotely and frequently, providing the sponsor with rich, real-world data outside of clinical sites in a more holistic, cost-effective and patient-centric fashion.

The new contract follows our successful collaborations with existing Cognition Kit partners and further negotiations with other major pharmaceutical companies are at an advanced stage.

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
Twitter
LinkedIn
Cambridge Cognition Holdings

More articles like this

Cambridge Cognition Holdings

Cambridge Cognition forms new Scientific Advisory Board

Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, is pleased to announce the formation of a Scientific Advisory Board. This expert board will provide scientific guidance and valuable market insights, primarily focusing

Cambridge Cognition Holdings

Cambridge Cognition Holdings Changes its Auditor to Crowe UK LL

Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced that the Board has approved the appointment of Crowe UK LLP as the Group’s new external auditor following a competitive

Cambridge Cognition Holdings

Cambridge Cognition strengthens balance sheet with £3 million loan

Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced that the Company has obtained a £3.0 million loan from Claret European Specialty Lending Company III, S.à r.l.  Claret specialises in

Cambridge Cognition Holdings

Cambridge Cognition Holdings Revision to Explanatory Note

Cambridge Cognition (LON:COG), which develops and markets digital solutions to assess brain health, has announced that the explanatory note to Resolution 7 in the Notice of the Annual General Meeting (“AGM”) to be held on 28 June 2023

Cambridge Cognition Holdings

Cambridge Cognition publishes Annual Report and Accounts

Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, has confirmed that the Annual Report and Accounts for the year ended 31 December 2022 and the Notice of the Annual General

Cambridge Cognition Holdings

Cambridge Cognition growth strategy clearly paying off (VIDEO)

Cambridge Cognition Holdings plc (LON:COG) CEO Matthew Stork joins DirectorsTalk Interviews to discuss prelim results for the year ended 31 December 2022. In this interview Matthew talks us through the result highlights, explains how the the acquisitions